Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for momentum i ...

Shares of Xeris Biopharma (XERS) have been strong performers lately, with the stock up 19.7% over the past month. The stock hit a new 52-week high of $9.41 in the previous session. Xeris Biopharma has gained 172.6% since the start of the year compared to the 0.7% gain for the Zacks Medical sector and the 8.1% return for the Zacks Medical - Drugs industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, having beaten the Zacks Consensus Estimate in each of ...

Core Insights - BioCryst Pharmaceuticals (BCRX) shares increased by 6.1% to $6.81, following a significant trading volume, contrasting with a 17.2% decline over the past month [1][2] Company Developments - The stock surge is attributed to a $700 million acquisition agreement for Astria Therapeutics, which will enhance BCRX's pipeline with navenibart, a long-acting injectable therapy for hereditary angioedema (HAE) [2] - The acquisition is expected to drive double-digit revenue growth, profit accretion, and rapid market adoption, indicating a strategic fit with BCRX's existing commercialization platform [2] Financial Performance Expectations - BioCryst is projected to report quarterly earnings of $0.06 per share, reflecting a year-over-year increase of 185.7%, with revenues anticipated at $161.15 million, a 37.6% rise from the previous year [3] - However, the consensus EPS estimate has been revised down by 4.8% over the last month, which may impact future stock price movements [4] Industry Context - BioCryst is categorized under the Zacks Medical - Drugs industry, where Ironwood Pharmaceuticals (IRWD) also operates, having seen an 8.8% increase in its stock price recently [4] - Ironwood's EPS estimate remains unchanged at $0.09, indicating a significant year-over-year change of 350% [5]

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Aquestive Therapeutics (AQST) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.Aquestive Therapeutics is a member of the Medical sector. This group includes 956 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stoc ...

Investors in BioCryst Pharmaceuticals, Inc. (BCRX) need to pay close attention to the stock based on moves in the options market lately. That is because the Mar 20, 2026 $2.00 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. ...

Core Insights - Aquestive Therapeutics (AQST) shares increased by 7.9% to $6.69, with a notable trading volume, contributing to a 27.1% gain over the past four weeks [1][2] Company Overview - The rise in stock price is attributed to positive expectations for Anaphylm, a key product candidate under FDA review for severe allergic reactions [2] - The USPTO granted two additional patents for Anaphylm, extending its protection until 2037 [2] Financial Performance - The company is projected to report a quarterly loss of $0.13 per share, unchanged from the previous year, with expected revenues of $13.36 million, a decrease of 1.3% year-over-year [3] - The consensus EPS estimate has remained stable over the last 30 days, indicating that stock price movements may not sustain without earnings estimate revisions [4] Industry Context - Aquestive Therapeutics holds a Zacks Rank of 3 (Hold), indicating a neutral outlook within the Zacks Medical - Drugs industry [5] - Comparatively, Madrigal (MDGL), another company in the same industry, experienced a 2% decline in its stock price, with a 1.6% return over the past month [5]

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even though momentum is a popular stock characte ...

Core Insights - Collegium Pharmaceutical (COLL) and Masimo Corporation (MASI) are highlighted as strong buy stocks due to rising earnings estimate revisions and their respective market positions in the medical sector [1][2]. Collegium Pharmaceutical (COLL) - Collegium is recognized as an undervalued specialty pharmaceutical company focusing on central nervous system, respiratory, and skin-related disorders [1]. - The company is projected to achieve a 20% increase in revenue and a 9% increase in earnings this year, with low-single digit growth expected for fiscal 2026 [3]. - Collegium's stock is trading at a forward earnings multiple of 5X and a sales multiple of less than 2X, significantly below the S&P 500 averages and the Zacks Medical-Drugs Industry average of 15.5X forward earnings and 3.4X forward sales [4]. - EPS projections for Collegium have risen to over $7 per share, distinguishing it from over 130 smaller-cap pharmaceutical companies that are currently unprofitable [5]. Masimo Corporation (MASI) - Masimo is noted for its non-invasive health monitoring systems, which provide real-time insights into patient physiology [2]. - The company is expected to see a 20% increase in annual earnings for FY25, reaching $5.30 per share, up from $4.40 last year, with a further 7% increase projected for FY26 [7]. - Masimo's stock trades at a forward earnings multiple of 26.5X, slightly above the Zacks Medical-Instruments Industry average of 23.5X, indicating a justified premium due to its growth prospects [7]. Market Context - Both Collegium and Masimo have experienced significant EPS revisions over the last 60 days, making them attractive options for growth and value in a market characterized by high volatility [9].

Company Overview - Zevra Therapeutics (ZVRA) shares increased by 10.4% to close at $8.95, following a period of 13.8% loss over the past four weeks, indicating a significant recovery in investor sentiment [1][2] - The surge in share price is attributed to positive investor expectations regarding Zevra's growth prospects, particularly related to its drug Miplyffa, which treats Niemann-Pick disease type C [2] Financial Performance - Zevra is expected to report a quarterly loss of $0.04 per share, reflecting a year-over-year change of +94.2%, while revenues are projected to be $26.53 million, up 619.1% from the previous year [3] - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, suggesting stability in earnings expectations [4] Industry Context - Zevra Therapeutics operates within the Zacks Medical - Drugs industry, which includes other companies like Nektar Therapeutics (NKTR), that recently saw a 1.2% increase in share price [4] - Nektar's consensus EPS estimate has decreased by 2.2% over the past month, indicating potential challenges within the industry [5]